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Doxazosin, a commonly prescribed treatment for patients 
with benign prostatic hyperplasia, serves as an α1-blocker of 
the adrenergic receptors. In this study, we calculated its effect 
on the ovarian carcinoma cell system and animal model. 
Doxazosin induces dose-dependent growth and time-
dependent suppression and is additively activated through IFN-
α or IFN-γ stimulation. At the same time, they both enhanced 
G1 phase arrest, as well as the activity of caspase-3 and PARP, 
and the reduction of cyclin D1 and CDK4 protein levels. 
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Doxazosin growth suppression was abolished either by the 
Janus family of tyrosine kinase (JAK) or the signal transducer 
and activator of transcription (STAT) inhibitor treatment. The 
activity of JAK/STAT was dependent on the level of doxazosin, 
suggesting a requirement of doxazosin for the activation of 
JAK/STAT. Furthermore, doxazosin plus IFN-α or doxazosin 
plus IFN-γ additively suppressed the activation of the 
JAK/STAT signals through phosphorylation of JAK and STAT, 
thus affecting the activation of subsequent downstream 
signaling components PI3K, mTOR, 70S6K and PKCδ. And in 
vivo study demonstrated that doxazosin significantly 
suppressed tumor growth in an ovarian xenograft model, 
inducing apoptotic cell death by up-regulating the expression 
of p53, whereas c-Myc expression was markedly reduced. 
Therefore, our data findings indicate that doxazosin can 
modulate the apoptotic effects of IFN-α and IFN-γ through 
the JAK/STAT signaling pathways. Collectively, we indicate 
that this action may be a potent chemotherapeutic property 
against ovarian carcinoma. Doxazosin also inhibited vascular 
endothelial growth factor (VEGF)-induced HUVEC migration as 
well as capillary-like structure tube formation in vitro. It also 
suppresses the expression of HIF-1α and VEGF in ovarian 
carcinoma cells. Doxazosin inhibited phosphorylation of 
vascular endothelial growth factor receptor-2 (VEGFR-2) and 
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transcription of VEGFR-2. Doxazosin inhibited PI3K, Akt, 
PDK1 and mTOR phosphorylation but had no effect on ERK1/2 
phosphorylation by VEGF treatment. Our results provide 
evidence for the cellular function in endothelial cell system that 
is relevant to angiogenesis through the inhibition of the 
Akt/mTOR phosphorylation by interacting with VEGFR-2. 
Furthermore, doxazosin prohibited VEGFR-2 phosphorylation 
and suppressed tumor vascularization in a xenograft model of 
human ovarian cancer. We found the biological function of 
doxazosin to be a potent anti-ovarian cancer agent by inhibition 
of JAK/STAT phosphorylation and anti-angiogenic agent by 
suppression of VEGFR-2 signaling pathway. Therefore, 
doxazosin combination therapies may be a more useful 
approach for more advanced ovarian cancers and recurrent 
patients 
Keywords:  doxazosin, ovarian cancer, IFN, JAK, STAT, 
VEGFR-2, Akt, mTOR,  
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4E-BP1: eukaryotic translation initiation factor 4E-binding 
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CDK4: cyclin-dependent kinase 4 
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Ovarian cancer chemotherapy  
Ovarian cancer is the second most lethal gynecological cancer 
in Korea, after uterine cervix cancer (Table 1). In 2008, the 
ovarian cancer incidence rate in Korea was similar to that in 
women worldwide and lower than that in Western countries 
(Figure 1). The crude ovarian cancer rate in Korea was 8.0 in 
2011 (Figure 2). The incidence has increased steadily in 
Korean women because Korean women showed rapid changes 
in nutritional, reproductive, and anthropometric factors (Park et 
al., 2010). In 2014, there will be an estimated 21,980 new 
ovarian cancer cases in the USA, with 14,270 deaths (Informed 
from NCI’s PDQ® , 2014). 
 Most patients with ovarian cancer are diagnosed at a late 
stage due to the lack of effective screening methods and 
specific symptoms associated with early stage disease (Buys et 
al., 2011; Dasari et al., 2014). Ovarian cancer-associated 
mortality rates have increased in Korea (Park et al., 2010). 
Ovarian epithelial cancer, the most common type of ovarian 
cancer (observed in approximately 90% of cases) is thought to 
originate from epithelial cells covering the ovaries. Although 
ovarian cancers are all epithelial in origin, they display four 
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distinct histologies—serous, mucous, clear cell, and 
endometrioid—that correlate with distinct gene expression 
patterns and with distinct sensitivity to therapies. At early 
stages (stages 1-2), current therapies include surgery, 
chemotherapy, and/or radiation therapy. At later stages, 
debulking surgery is combined with platinum- or taxane-based 
chemotherapy (intraperitoneal or external) and, potentially, 
radiation therapy. However, 80% of patients will relapse after 
first-line platinum- or taxane-based chemotherapy, and 
conventional therapeutic protocols have so far given 
disappointing results. There is a need for new therapeutic drugs, 
and agents that target neo-angiogenesis are an interesting 
prospect. Ovarian cancer comprises a variety of tumors that 
involve the ovarian tissues and arise from Müllerian tissues, 
including the distal fallopian tube and endometrium. Histologic 
and clinical features, as well as associated finding such as 
mutations, expression profiles, pathway activation, and genome 








Table 1. Major cancer sites by sex, Korean, 2011  
(Modified from ‘annual report of cancer statistics in Korea in 
2011, NCC’, 2013). 
(Unit: cases, %, rate per 100,000) 
Rank Site Cases % CR ASR 
 
All cancers   107,866  100.0 431.0 316.7 
1 Thyroid     33,562  31.1 134.1 113.8 
2 Breast     15,942  14.8 63.7 50.0 
3 Colon and rectum     10,955  10.2 43.8 27.6 
4 Stomach     10,293  9.5 41.1 26.9 
5 Lung       6,586  6.1 26.3 15.5 
6 Liver       4,274  4.0 17.1 10.5 
7 Cervix uteri       3,728  3.5 14.9 11.7 
8 Gallbladder etc       2,514  2.3 10.0 5.6 
9 Pancreas       2,273  2.1 9.1 5.2 
10 Ovary       2,010  1.9 8.0 6.2 









(Incidence rate per 100,000, age-standardized, Segi standard population)   
Figure 1. Global incidence rates for ovarian cancer in year 2008 



































Figure 2. Korean crude rates for ovarian cancer in year 2011 




Table 2. Disease types and characteristics of ovarian cancer 
(Bookman et al., 2014). 
Destriptors HGSC CCC EC MC LGSC 
Percentage of 
cases      
  FIGO I-II 39% * 33% 22% 5% 1% 
  FIGO III-IV 86% * 2% 7% 2% 3% 
Genetic risk 
factors 


























Adnexal mass Adnexal mass Adnexal mass Gi symptoms 


























































None known None known 








HER2/neu BRAF, MEK 
 
CCC:clear cell carcinoma; EC:endometrioid carcinoma; GI:gastrointenstinal; 
HGCS:high-grade serous carcinoma; HRD:homologous recombination deficiency; 
HRT:hormone replacement therapy (postmenopausal); LGSC: low-grade serous 
carcinoma; MC:mucinous carcinoma; MSI:microsattelite instability; OC:oral 
contraceptive; RRBSO:risk-reducing bilateral salpingo-oophorectomy; * Includes 
mixed histology tumors with high-grade features. 
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As described by the American Cancer Society, chemotherapy is 
the use of drugs to treat cancer. The standard approach is to 
combine anti-cancer drugs, such as cisplatin, carboplatin and a 
taxanes (paclitaxel and docetaxel). Ovarian tumors are 
attenuated or even eliminated by chemotherapy, but some 
cancer cells may eventually regrow. Chemotherapeutic drugs 
kill cancer cells but also damage some normal cells (Informed 
from NCI’s PDQ® , 2014). For example, cisplatin has been linked 
to crosslinking with the purine bases in DNA. This interferes 
with DNA repair mechanisms, causing DNA damage and 
subsequently inducing apoptosis in cancer cells. However, there 
are numerous undesirable side effects such as severe kidney 
problems, allergic reactions, decreased immunity, 
gastrointestinal disorders, hemorrhage, and hearing loss, 
especially in younger patients. Despite its severe side effects 
and the development of resistance, cisplatin is used as the 
major treatment of ovarian cancer (Dasari et al., 2014). Taxane 
is a well-known mitotic inhibitor that binds to microtubules, 
thereby inhibiting their reorganization. Taxanes such as 
paclitaxel (Taxol) and docetaxel (Taxotere) are first-line 
treatments for breast, ovarian, lung, and other metastatic 
cancers, but they cause multidrug resistance and side effects 
(Dasari et al., 2014; Fauzee et al., 2011). A recent targeted 
therapy in ovarian cancer is the humanized monoclonal antibody 
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bevacizumab (Avastin), which blocks angiogenic signaling. 
Bevacizumab has been shown to decrease or delay the growth 
of ovarian cancer. However, there have been problems with 
perforations of the bowel wall during treatment, which can be 
fatal to patients (Keating et al., 2014). Traditional approaches 
to anti-cancer drug development are being increasingly 
challenged by the numerous potential targets and candidate 
drugs. Thus, it is sometimes useful to study multiple markers 
and cancer-related molecular cascades to reduce the side 




Interferons and JAK/STAT pathway 
Interferons (IFNs) are a glycoprotein known as a part of the 
cytokine superfamily, and they regulate the response of the 
immune system, such as the infection against viruses, parasites, 
bacteria, and even the response for cancer cells by mediating 
the action of various types of genes (Chawla-Sarkar et al., 
2003; Cheon et al., 2014; Morikawa et al., 1987; Stark et al., 
1998; Takaoka et al., 2003). IFN-α is a key indicator for 
viral infections through Toll-like receptors (TLRs), where 
macrophages and natural killer (NK) cells are induced, which 
enhances lymphocytes antigen presentation (Cheon et al., 2014; 
Pirhonen et al., 2007). IFN-γ is a secreted protein that serves 
as a regulator of macrophage activation, where it appertains to 
the type II class of the interferon family. It is also activated by 
specific antigen presentation and can induce apoptosis. In 
addition, IFN-γ can induce the anti-tumor effect, anti-viral, 
and immunoregulatory of the type I interferons, such as IFN-α, 
IFN-β, IFN-ω, IFN-κ and IFN-ε(Burke et al., 1999; 
Schroder et al., 2004). In the biological function, IFNs are 
multifunctional factors that signal through the JAK/STAT 
pathway in the activation of STAT1/2 (Figure 3) (Pestka et al., 









Figure 3. Interferon receptors and activation of classical JAK–
STAT pathways (Modified from Platanias et al., 2005). 
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The JAK/STAT pathways are involved in the regulation of 
various cellular events including cell proliferation, 
differentiation, hematopoiesis, development, and apoptosis. 
They are activated by the binding of cell-surface receptors, 
such as interferons, growth factors, and interleukins (Aaronson 
et al., 2002; O’Shea et al., 2004). Interrupted or non-
regulated JAK/STAT function can result in various proliferative 
disorders and immune disorders. Instance, STAT3 is 
continuously up-regulated in various tumors while JAK 
activation induces cell proliferation, cell migration, and 
apoptotic cell death (Darnell et al., 2005). Interestingly, STAT3 
up-regulates various proteins involved in cell cycle 
progression, such as c-Myc, and cyclin D1, and induces anti-
apoptotic proteins, such as Bcl-2 and Bcl-xL (Barre et al., 
2003). Thus, STATs target proteins are important mediators 






Angiogenesis is initiated by growth factors such as VEGF and 
bFGF(basic fibroblast growth factor) and is a potential 
treatment for vascular injuries (Yoshiji  et al., 1996; Gavin et al., 
2004; Kraus et al., 2004). During cancer progression, 
endothelial cell activity plays an essential role in modulating 
various vascular physiological and pathological functions. 
VEGFR-2 plays a pivotal role in the activation of downstream 
components that are responsible for proliferation, including 
endothelial cell invasion, migration, differentiation and 
embryonic angiogenesis (Breier et al., 2000; Ferrara et al., 
2000; Meyer et al., 2003) in contrast, VEGFR-1 has no role in 
endothelial cell proliferation (Meyer et al., 2004). VEGFR-2 
exerts its function through the PI3K/Akt/mTOR signaling 
pathway in endothelial cells, the activation status of VEGFR-2 
was studied by determining phosphorylation of VEGFR-2 itself 
together with phosphorylation of downstream targets of mTOR 
(Figure 4)(Trinh et al., 2009). In addition, Trinh observed the 
correlation between the activated status of the VEGFR-2 and 
downstream markers of the AKT/mTOR signal pathway, pS6 
and p4E-BP1 protein, using human ovarian cancer samples 
(Table 3) and suggested that anti-VEGF treatments are 
suppressors of acting as a surrogate AKT/mTOR signalling 









Figure 4. VEGFR-2 activation VEGFR-2 exerts its function 
through the PI3K/Akt/mTOR signaling pathway in endothelial 







Table 3. Immunostaining and marker correlative study summary 
of clinical data (Trinh et al., 2009).                                    
(N=89 patients) 






FIGO I 19 270 275 20 100 
FIGO II 4 285 100 45 125 
FIGO III 56 210 100 20 90 
FIGO IV 10 300 180 150 160 
  
NS NS NS NS 
Grade 1 20 300 200 30 90 
Grade 2 27 180 80 15 80 
Grade 3 42 300 100 20 160 
  
P=0.06 NS NS P=0.085 
Serous paplliary 47 270 180 20 80 
Mucinous 4 195 250 20 95 
Endometrioid 23 210 80 25 160 
Clear cell 10 195 50 40 95 
  
NS NS NS NS 
Total 89 240(0-300) 160(0-300) 20(0-300) 100(0-300) 
  
Median H-scores are reported. P-values (Kruskal –Wallis tests) are reported in case 




Doxazosin, is a quinazoline compound that is a selective 
inhibitor of the α1-adrenergic receptors. The chemical name 
of doxazosin mesylate is 1-(4-amino-6,7-dimethoxy-2-
quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine 
methanesulfonate (Kirby et al., 1997). They have function to 
block α-receptors in relaxing blood vessels and reducing the 
speed and force of the heart contractions (Akduman et al., 
2001). It is used for treatment of patients with benign prostatic 
hyperplasia, a noncancerous enlargement of the prostate gland, 
because α1-blockers relax the smooth muscle tissue 
surrounding the prostate, easing urine to flow and decreasing 
bladder outlet obstruction (Benning et al., 2002; 
Tahmatzopoulos et al., 2004). Some previous studies also 
reported that α1-adrenoceptor antagonists stimulate apoptotic 
cell death via TGF-β1 signaling and the activation of clear 
factor of kappa light polypeptide gene enhancer in IκBα in 
prostate tumor cells (Benning et al., 2002; Partin et al., 2003). 
Doxazosin also stimulates apoptotic cell death in response to 
abnormal cell-matrix interactions (Keledjian et al., 2003). 
Garrison et al. reported that specific caspase-8 inhibitors could 
block doxazosin-induced apoptotic cell death in benign prostate 




In previous studies, doxazosin relaxed the smooth muscles 
surrounding the prostate and stimulated apoptotic cell death in 
prostate hyperplasia (Keledjian et al., 2003; Garrison et al., 
2006). However, the biological roles of these doxazosin-
regulated processes, as well as the molecular mechanism 
behind the anti-angiogenic effects of doxazosin, remain poorly 
understood. This study evaluated the effects of doxazosin on 
ovarian cancer as an anti-tumorigenesis and anti-angiogenic 















DOXAZOSIN SUPPRESSES JAK/STATs PHOSPHORYLATION 





Doxazosin, a commonly prescribed treatment for patients with 
benign prostatic hyperplasia, serves as an α1-blocker of the 
adrenergic receptors. In this study, we calculated its effect on 
the ovarian carcinoma cell system. Doxazosin induces dose-
dependent growth suppression and is additively activated 
through IFN-α or IFN-γ stimulation. At the same time, they 
both enhanced G1 phase arrest, as well as the activity of 
caspase-3, and the reduction of cyclin D1 and CDK4 protein 
levels. Doxazosin growth suppression was abolished either by 
the JAK or the STAT inhibitor treatment. The activity of 
JAK/STAT was dependent on the level of doxazosin, 
suggesting a requirement of doxazosin for the activation of 
JAK/STAT. Furthermore, doxazosin plus IFN-α or doxazosin 
plus IFN-γ additively suppressed the activation of the 
JAK/STAT signals through phosphorylation of JAK and STAT, 
thus affecting the activation of subsequent downstream 
signaling components PI3K, mTOR, 70S6K, and PKCδ. In vivo 
study demonstrated that doxazosin significantly suppressed 
tumor growth in an ovarian xenograft animal model, inducing 
apoptotic cell death by up-regulating the expression of p53, 
whereas c-Myc expression was markedly reduced. Therefore, 
our data findings indicate that doxazosin can modulate the 
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apoptotic effects of IFN-α and IFN-γ through the 
JAK/STAT signaling pathways. Collectively, we indicate that 







-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfo 
nate, quinazoline compound, is known as an α1-blocker of 
adrenergic receptors (Kirby et al., 1997). Generally, α1-
blockers have similar abilities to α-blockers during biological 
functions, where they function to block α-receptors in the 
blood and heart physiological system, such as relaxing blood 
vessels and reducing the speed and force of the heart 
contractions (Akduman et al., 2001).  
Interferons (IFNs) are a glycoprotein known as being part of 
the cytokine superfamily, and are known to regulate the 
response of the immune system, such as during invasions from 
viruses, parasites, bacteria, and cancer cells. IFNs directly 
control the immune system response and decrease the growth 
of carcinoma cells by mediating the action of various types of 
genes (Stark et al., 1998; Chawla-Sarkar et al., 2003). In 
addition, IFNs regulate the phosphorylation of STAT by 
interacting with their specific receptor. IFN-α is directly 
developed from leukocytes and are mostly involved in both 
anti-viral and immunoregulatory activities at target cells. IFN-
α is also a key indicator for viral infections through Toll-like 
receptors (TLRs), where macrophages and natural killer (NK) 
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cells are induced, which enhances antigen presentation to 
lymphocytes (Morikawa et al., 1987; Takaoka et al., 2003;  
Pirhonen et al., 2007). IFN-γ is a secreted protein that serves 
as a regulator of macrophage activation, where it appertains to 
the type II class of the interferon family. It is also activated by 
specific antigen presentation and can induce apoptosis. In 
addition, IFN-γ can induce the anti-tumor effect, anti-viral, 
and immunoregulatory of the type I interferons, such as IFN-α, 
IFN-β, IFN-ω, IFN-κ and IFN-ε(Rinderknecht et al., 1984;  
Dufour  et al., 2004; Schroder et al., 2004). Previous studies 
have demonstrated that IFN-γ can either direct anti-
proliferative activity or induce apoptotic cell death in some 
ovarian carcinoma cell types, as well as in primary carcinoma 
cells and mouse tumor model systems (Chawla-Sarkar et al., 
2003; Burke et al., 1999;  Kim et al., 2002; Wall et al., 2003). 
The JAK/STAT pathways are involved in the regulation of 
the immune system for various cellular events including cell 
proliferation, differentiation, hematopoiesis, development, and 
apoptosis. They are activated by the binding of cell-surface 
receptors, such as the bindings by interferons, growth factors, 
and interleukins (Aaronson et al., 2002; O’Shea et al., 2004). 
Interrupted or non-regulated JAK/STAT functionality can 
result in various cancers and immune disorders. For instance, 
STAT3 is continuously up-regulated in various tumors, 
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including major carcinomas and some hematologic cancers, 
while JAK activation induces cell proliferation, cell migration, 
and apoptotic cell death (Darnell et al., 2005). 
Doxazosin is also prescribed to patients with benign 
prostatic hyperplasia, a non-cancerous enlargement of the 
prostate gland, because α1-blockers alleviate the smooth 
muscles surrounding the prostate, easing urine flow and 
decreasing bladder outlet obstruction (Benning et al., 2002;  
Tahmatzopoulos et al., 2004). However, the side effects of 
α1-blockers include fainting, headache, orthostatic 
hypotension, heart palpitations, dry mouth, and nasal congestion. 
These drugs can also cause erectile dysfunction, although not 
as frequently as some other blood pressure medications. In 
some studies, α1-adrenoceptor antagonists have induced 
apoptotic cell death through the TGF-β1 signaling IκBα 
activation in prostate carcinoma cells (Benning et al., 2002;  
Partin et al., 2003). Doxazosin has also been validated to induce 
apoptotic cell death, in which the antagonistic effector is 
triggered by abnormal cell-matrix interactions (Keledjian et al., 
2003). In a recent study, doxazosin-mediated apoptosis could 
be blocked by specific caspase-8 inhibitors in benign prostate 
cells (BPH). Caspase-8 activation is initiated by its interaction 
with FADD and their subsequent recruitment by doxazosin 
(Garrison et al., 2006). Howevere, the details of the molecular 
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mechanism of these doxazosin-mediating processes are still 
poorly understood. 
This study was designed to explore the major roles of the 
critical components in the cellular signaling pathways, such as 
JAK/PI3K/STAT phosphorylation, accompanied by the patterns 
of expression of apoptosis-related proteins by doxazosin-
induced apoptosis along with the underlying molecular 
mechanisms of ovarian carcinoma cells. 
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Materials and Methods 
 
Cell lines, drug reagents and antibodies 
Human ovarian cancer cell lines (OVCAR-3, 2774 and SKOV-
3) were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). Human IFN-α and IFN-γ were 
obtained from Sigma (St. Louis, MO). The chemical doxazosin 
was also purchased from Sigma (St. Louis, MO). The JAK1/2 
kinase inhibitor INCB18424 (Ruxolitinib) and STAT1 inhibitor 
(NSC118218) were obtained from Selleck Chemicals (Houston, 
TX), and stock solutions were prepared in DMSO. NSC74859 
(S31-201), a specific STAT3 inhibitor, was purchased from 
Calbiochem Chemicals (La Jolla, CA). The following primary 
antibodies were used in this study: anti-JAK1, anti-phospho-
JAK1, anti-JAK2, anti-phospho-JAK2, anti-STAT1, anti-
phospho-STAT1, anti-STAT3, anti-phospho-STAT3, anti-
caspase-3, and anti-cMyc, anti-Bcl-2, anti-Bax, anti-p53, 
anti-survivin, and anti-COX-2 (Cell Signaling, Beverly, MA), 
anti-PARP, anti-XIAP (BD Biosciences, San Jose, CA), anti-
cyclin D1, anti-CDK4, anti-Akt, anti-phospho-Akt, anti-
TYK2, anti-phospho-TYK2, anti-PI3K, anti-phospho-PI3K, 
anti-mTOR, anti-phospho-mTOR, anti-PKCδ, anti-
phospho-PKC, anti-STAT2, anti-phospho-STAT2, anti-
p70S6K, and anti-phospho-p70S6K (Santa Cruz Biotechnology, 
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Santa Cruz, CA), anti-p16, anti-p21, and anti-p27 (Oncogene, 
San Diego, CA). 
 
Cytotoxicity assay 
Cell viability was evaluated using 3-(4,5-dimethylthiazol-2-
yl)-2.5-diphenyl-2H-tetrazolium bromide (MTT) assays. 
Briefly, cells were seeded at 5.5×103 cells per well in 96-well 
plates. Then, the cells were treated with doxazosin, IFN-α or 
IFN-γ and 20 μl of MTT solution (Sigma, 5 mg/ml) were 
added to each well. The plate was incubated for an additional 4 
h at 37℃. The MTT reaction was terminated with DMSO. 
 
Cell cycle analysis 
Ovarian carcinoma cells were plated onto chamber slides at a 
density of 4.5×104 cells per well and were then treated. A cell 
cycle distribution was performed through fluorescence-
activated cell sorting (FACS). Cells were harvested by trypsin 
treatment and rinsed twice with phosphate buffered saline 
(PBS). After centrifugation, cells were incubated with FITC-
labeled Annexin V and propidium iodide (PI) for 15 min 







Cells and tissues were collected, rinsed twice with cold PBS, 
and lysed using RIPA lysis buffer with protease inhibitor 
cocktail (Sigma) at 4℃ for 50 min. Cell lysates containing equal 
amounts of protein were subsequently separated with 8~12% 
SDS-PAGE, where they were then transferred onto Hybond-
ECL nitrocellulose membrane (GE Healthcare, UK). After 
blocking, the membranes were incubated with the appropriate 
primary antibodies at 4℃ overnight. The membranes were 
washed thrice with TBST buffer and incubated in either goat 
anti-rabbit or anti-mouse secondary antibodies. 
 
Xenograft mouse model 
Specific pathogen-free BALB/c - nu/nu mice (5~6 weeks old) 
were purchased from Orientbio (Sungnam, Korea). All animal 
studies were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the Research Institute of the National 
Cancer Center. To establish ovarian tumors in mice, 1.0×106 
SKOV-3 cells were injected subcutaneously with Matrigel (BD 
Bioscience, MA) into the left mid-dorsal region of each nude 
mouse. Tumors were allowed to grow for 10 days. Tumor sizes 
were measured by caliper measurements 3 times every week. 
On day 10, oral treatment of 3 mg/kg of doxazosin was done and 
repeated 5 times per week for 30 days. Mice were sacrificed 
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one day after the final treatment, and tumors were then fixed 
10% neutral bufferd formalin (NBF) for paraffin blocks and 
stored at -80℃ for further study. 
 
Statistical analysis 
Data are expressed as the mean±SD of error for the mean of 
the triplicate experiments. Statistical analyses were performed 
using Student’s t-test for comparisons between the two groups. 
The index for statistical significance was P<0.05. The values 
with 95% confidence (P<0.05) are depicted with an asterisk (*) 





Doxazosin inhibits cell proliferation in a dose-dependent manner, 
and additively enhances apoptotic cell death by IFN-α and 
IFN-γ treatment 
To study the biological function of doxazosin during IFN-α or 
IFN-γ treatment in ovarian carcinoma cells, we elected to use 
a treatment of doxasozin which is known as an α1-blocker of 
adrenergic receptors. The cell viability of SKOV-3 cells 
treated with various concentrations (0, 10, 20, 30, and 40 μM) 
of the doxazosin drug were decreased in a dose-dependent 
manner, where the doses were required to suppress the growth 
of the cells by 40%, which exceeded 20 μM on SKOV-3 
ovarian carcinoma cell line (Figure 5). Similar results of the 
pro-apoptotic effect were shown by other ovarian carcinoma 
cells, such as 2774 (Figure 6) and OVCAR-3 (data not shown). 
We then examined the apoptotic activity of doxazosin through 
IFN-α and IFN-γ treatment, respectively. As presented in 
Figure 7, the effect of each doxazosin, IFN-α, and IFN-γ on 
SKOV-3 cells, decreased the number of cells, which is 
indicative of cell viability. IFN-α treatment significantly 
reduced the proliferation in the cells. The cell viability of IFN-
α-treated SKOV-3 cells was inhibited to approximately 60% 
when compared to the untreated SKOV-3 cells. In contrast, 
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doxazosin and IFN-γ weakly inhibited the SKOV-3 cells. We 
also calculated the potential additive or synergistic effects of 
doxazosin in combination with IFN-α or IFN-γ in ovarian 
tumors. As shown in Figure 8, co-treatment with doxazosin and 
IFN-γ or IFN-α had an additive effect, indicating that 
doxazosin plus either, IFN-α or IFN-γ additively inhibits cell 
growth in a time-dependent manner. The cytotoxicity of the 
doxazosin/IFN-α or IFN-γ combination on carcinoma cells 
were evaluated using fluorescence activated cell sorting 
(FACS) with the FITC-labeled Annexin V. As presented in 
Figure 9, pre-treatment with IFN-α or IFN-γ dramatically 
promoted doxazosin-induced apoptotic cell death, showing that 
IFN-α or IFN-γ enhances doxazosin-mediated cell growth 
inhibition. Caspases can be activated through intrinsic or 
extrinsic signaling pathways. Caspase-3 is a critical apoptotic 
molecule, as it is responsible for the proteolytic cleavage of 
various regulatory proteins, such as PARP. To confirm the 
increased activity of the cleaved caspase-3, the 
immunoblotting of major caspase-3 and cleaved caspase-3 
involved in the apoptotic pathways is presented in Figure 10. 
The immunoblotting results that were clearly observed 
dramatically enhance the activity of caspase-3 with doxazosin 
alone, doxazosin plus IFN-α, or doxazosin plus IFN-γ 
treatment. Subsequently, the cleavage of PARP induced by 
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doxazosin alone was also additively induced by the combination 







Figure 5. Effects of doxazosin on cell proliferation in SKOV-3 
ovarian carcinoma cells.   
Exponentially-growing cells were treated with increased 
concentrations of doxazosin (0~40 μM). Doxazosin drug were 
decreased in a dose-dependent manner, where the doses were 
required to suppress the growth of the cells by 40% in SKOV-







Figure 6. Effects of doxazosin on cell proliferation in 2774 
ovarian carcinoma cells.   
Exponentially-growing cells were treated with increased 
concentrations of doxazosin (0~40 μM). Doxazosin drug were 
decreased in a dose-dependent manner, where the doses were 











Figure 7. Effects of doxazosin, IFN-α and IFN-γ stimulation 
on ovarian carcinoma cell viability.    
SKOV-3 cells were treated with doxazosin, IFN-α or IFN-
γ and the cell viability was measured using a MTT 
colorimetric assay. Significant differences of 95% confidence 










Figure 8. Additive effects of doxazosin by IFN-α or IFN-γ 
stimulation on ovarian carcinoma cell viability.  
IFN-α and IFN-γ-stimulated SKOV-3 cells were treated for 
the indicated times with doxazosin. Significant differences of 
95% confidence (P<0.05) are depicted with an asterisk (*) for 









 Figure 9. Additive effects of doxazosin by IFN-α or IFN-γ 
stimulation on ovarian cell proliferation.  
Cells were treated with control (untreated) or doxazosin alone 
or in combination (doxazosin plus IFN-α and doxazosin plus 
IFN-γ) where the data calculated the additive effects of 





 Figure 10. Caspase-3 cleavages activated by doxazosin, 
doxazosin plus IFN-α, or doxazosin plus IFN-γ treatments.  
Soluble protein extracts were introduced by immunoblotting for 
pro-caspase-3 and cleaved caspase-3. β-actin was used to 
verify equal loading. 
 
        
 
Figure 11. PARP cleavages activated by doxazosin, doxazosin 
plus IFN-α, or doxazosin plus IFN-γ treatments.  
Soluble protein extracts were introduced by immunoblotting for 




Effect of doxazosin on IFN-α or IFN-γ-stimulated expression 
of cell cycle modulator proteins 
To investigate whether cell cycle arrest is related to the 
expression of the cell cycle regulatory proteins, as well as 
changes to the cell cycle distribution, cells were treated at 
various times with the indicated doxazosin, IFN-α, IFN-γ or 
combination, followed by FACS, and were then immunoblotted 
for analysis. As presented in Figure 12 (upper panel), the cell 
cycle profile of the control (untreatment) cells did not change 
significantly, except that of the S phase section gradually 
decreasing due to doxazosin, IFN-α or IFN-γ treatment, 
respectively. In addition, the cell cycle profile of the cells 
treated with the doxazosin plus IFN-α or doxazosin plus IFN-
γ combinations arrested the G1 phase when compared to the 
doxazosin single-drug treatment Figure 12 (lower panel). 
Interestingly, the greatest pro-apoptotic effect occurred with 
the combination of 20 μM of doxazosin and 10 ng of IFN-α. 
These results suggest that the induction of apoptotic cell death 
is contributed by the doxazosin plus IFN-α-mediated anti-
tumor effect. The expression of cyclin D1 and CDK4, which are 
relevant to the conversion from the G1 to S phase, was inhibited 
in a time-dependent manner. In addition, cyclin-dependent 
kinase inhibitors p21 and p27, which typically cause cells to 
delay cell cycle progression in the G1 phase, were induced in 
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the doxazosin, IFN-α or IFN-γ-treated cells (Figure 13). 
Consistent with these findings, a decrease in cyclin D1 and 
CDK4 protein levels in response to the combined treatment was 
greater than that of doxazosin, IFN-α or IFN-γ-treated 
alone cells (Figure 14). Taken together, our findings indicate 
that doxazosin, IFN-α and IFN-γ inhibit cell proliferation by 





Figure 12. Effects of doxazosin on IFN-α or IFN-γ stimulation 
on cell cycle distribution.  
Cells were pre-treated with IFN-α or IFN-γ then with 
doxazosin (lower panel), collected, and analyzed using flow 
cytometry. The cell cycle distribution was assessed form the 








Figure 13. Effects of doxazosin and IFN-α or IFN-γ-
stimulated on the expression levels of cell cycle-associated 
proteins.  
Cells were treated to compare with a time-course of shorter 
times by using the indicated control (untreated cells), 
doxazosin alone, IFN-α alone, IFN-γ alone. Cell lysates 
were immunoblotted with the indicated antibodies (p21, p27, 










Figure 14. Effects of doxazosin with IFN-α or IFN-γ 
combination on the expression levels of IFN-α or IFN-γ 
stimulated cell cycle-associated proteins.  
Cell lysates were immunoblotted with the indicated antibodies 




Doxazosin inhibits phosphorylation of JAK/STAT 
Considering the propagation of JAK/STAT activation in 
malignant cancer and the requirement of the various 
biological/physiological responses for cell proliferation, 
understanding how JAK/STAT activation regulates the 
phosphorylation levels and cellular signal transduction 
processes is very important. JAK proteins are phosphorylated 
when cytokines bind to their specific receptors, subsequently 
activating STATs. STATs are a family of cytoplasmic proteins 
with Src homology-2 (SH2) domains that act as signal 
messengers and transcription factors (Dell'Albani et al., 2003). 
Based on the findings presented, we examined whether 
doxasoxin suppressed the phosphorylation of JAK and STATs 
in carcinoma cells. As presented in Figure 11 and Figure 12, 
phosphorylation of JAK and STAT were dramatically reduced 
by the doxazosin drug. In addition, JAK and STAT inhibitor 
treatment exactly recovered doxazosin-reduced phospho
rylation of both JAK1/2 and STAT1/3. Consistent with the 
results observed in carcinoma cells, inhibitors for JAK and 
STAT also significantly blocked doxazosin-reduced JAK or 
STAT activity (Figure 15 and Figure 16). Taken together, 
these results suggest new insight into the anti-tumor effects 





Figure 15. JAK inhibitors block doxazosin-mediated JAK 
dephosphorylation.  
Cells were treated with control (untreated cells), doxazosin, 
doxazosin plus JAK1/2 inhibitor respectively. Levels of JAK1 
(total and p-Y1022/1023), JAK2 (total and p-Y1007/1008) 
were developed by Western blotting(upper panel). Cells were 
treated for the indicated times with the indicated drug agents 
(lower panel). Experiments were performed in triplicate and 




Figure 16. STAT inhibitors block doxazosin-mediated STAT 
dephosphorylation. 
Cells were treated with control (untreated cells), doxazosin, 
doxazosin plus STAT1/3, respectively. Levels of STAT1 (total 
and p-Y701) and STAT3 (total and p-Y705) were developed 
by Western blotting(upper panel).. Cells were treated for the 
indicated times with the indicated drug agents (lower panel). 
Experiments were performed in triplicate and error bars are 
shown as the mean±SD. *P<0.05. 
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Decreased phosphorylation of PI3K/Akt/mTOR as well as 
70S6K and PKCδ following doxazosin treatment 
IFNs are crucial regulators of the JAK/STAT signaling pathway. 
The IFN-α/γ receptors consist of two subunits of IFNR-1 
and IFNR-2. Generally, activation of the JAK kinase family 
(JAK1 and TYK2) followed by the phosphorylation of the 
STAT1/2 proteins. In contrast, IFN-γ leads to the 
phosphorylation of the JAK1/2 tyrosine kinases, resulting in the 
phosphorylation of STAT1 through the binding of its receptor. 
As with previous evidence, immunoblotting was employed to 
evaluate the effect of doxazosin on the JAK/STAT signaling 
pathway molecules, such as Tyk2, PI3K, Akt, mTOR, 70S6K, 
and PKCδ phosphorylation. Generally, active PI3K/Akt 
induces cell proliferation as well as protein synthesis through 
the activation of the mTOR and 70S6K genes. Cells were 
treated with 20 μM doxazocin, 20 μM doxazoxin plus 10 ng 
IFN-α or 20 μM doxazosin plus 10 ng IFN-γ respectively. 
As presented in Figure 17 and Figure 18, doxazoxin down-
regulates phospho-JAK1/2 and STAT1/3, but not the total 
JAK1/2 and STAT1/3. Consistent with this, doxazosin plus 
IFN-α or IFN-γ additively inhibited the activation of the 
JAK/STAT pathway, and thus affected subsequent downstream 
signaling components, including PI3K, mTOR, 70S6K, and 
PKCδ activation. Overall the results validated that doxazosin 
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can potentiate the effects of IFN-α or IFN-γ through 
JAK/STAT/mTOR signaling pathway-dependent apoptotic cell 
death, as well as increasing G1 phase arrest of the cell cycle 







Figure 17. Doxazosin and doxazosin plus IFN-α combination 
down-regulates the phosphorylation of the major components of 
the JAK/STAT/mTOR-mediated signaling pathways.  
Cells were treated with control (untreated cell), doxazosin 
alone, doxazosin plus IFN-α or doxazosin plus IFN-α. 
Western blots for the non-phosphorylated proteins were used 







Figure 18. Doxazosin and doxazosin plus IFN-γ combination 
down-regulates the phosphorylation of the major components of 
the JAK/STAT/mTOR-mediated signaling pathways.  
Cells were treated with control (untreated cell), doxazosin 
alone, doxazosin plus IFN-γ or doxazosin plus IFN-γ. 
Western blots for the non-phosphorylated proteins were used 
as a loading control (JAK1, JAK2, STAT1, STAT2, STAT3, 
PI3K, Akt, PKCδ). 
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Doxazosin inhibits tumor growth in nude mice 
We investigated the growth-inhibitory effect of doxazosin on 
ovarian carcinoma cells in vivo. For this purpose, 
Exponentially-growing SKOV-3 ovarian cells were implanted 
subcutaneously into immune-deficient BALB/c-nu/nu mice. We 
allowed the tumors to grow until they reached a mean volume 
of 50 mm3. Tumor growth was inhibited by doxazosin at the 
20th day, which reached a mean volume of 100 mm3 (Figure 
19). There were no differences in body weight loss or liver 
toxicity (data not shown). The volume of the treated tumors 
was 50~65% smaller than those of the control mice (Figure 20). 
Next, we examined the effect of doxazosin on p53 stabilization 
in tumor tissues collected from the control and doxazosin 
treated mice. Doxazosin treatment was observed to remarkably 
increase the level of p53 protein expression, whereas c-Myc 
expression was markedly reduced (Figure 21). Subsequently, 
to further clarify the biological mechanism of doxazosin-
induced cell cycle arrest. The protein levels of cell progression 
were examined with tumor tissue lysates. The expression 
levels of cyclin D1 and CDK4 protein, which is associated with 
the transition of G1 to S phase was significantly reduced, 
whereas the CDK cell cycle inhibitors p16 and p27, which are 
related with the interruption of cell cycle progression in the G1 
or G2/M phase, were enchanced (Figure 22, upper panel). In 
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addition, to address whether doxazosin induces apoptotic cell 
death, we evaluated the activation of caspase-3 for stimulation 
of apoptosis, as well as the activation of PARP through western 
bloti analysis. Expression of cell death-related proteins such as 
caspase-3 and PARP was remarkably increased in doxazosin-
treated tumors (Figure 22, lower panel). These results indicate 
that doxazosin is capable of inhibiting tumor growth by inducing 
apoptotic cell death in vivo. We next showed that Bax 
expression was increased in the doxazosin-treated group, but 
not in the control group (Figure 23, upper panel). Meanwhile, 
the protein expression of anti-apoptotic/oncogenic/anti-
proliferation genes, such as Bcl-2, surviving, COX-2, ICAM-1, 
XIAP were decreased in the doxazosin treatment group 
compared to the control group (Figure 23, lower panel). Taken 
together, these results showed that the treatment with 
doxazosin significantly inhibited tumor growth n the mouse 




Figure 19. Doxazosin suppresses tumor growth on ovarian 
carcinoma xenograft  mice.  
Subcutaneous tumors derived from the SKOV-3 (1.0 x 106) 
cells were treated with doxazosin as indicated and tumor 
growth was inhibited by doxazosin at the 20th day (lower 






Figure 20. Doxazosin suppresses tumor progression in nude 
mice.  
After sacrifice, image of the xenograft tumor mass treated with 
or without doxazosin (upper panel). Inhibitory effects of 
doxazosin on xenograft tumor weight indicated that the 
treatment mice tumors were 50~65% smaller than those of the 










Figure 21. Effect of doxazosin treatment on the expression level 
of p53 in SKOV-3 carcinoma cell-derived tumor.  
The expression level of p53 in SKOV-3 carcinoma cell-
derived xenograft tumors excised on the 31st day post-
treatment, p53 and c-Myc expressions measured using 








Figure 22. Effect of doxazosin treatment on the expression level 
of cell cycle and apoptosis in SKOV-3 carcinoma cell-derived 
tumor. 
From xegrafted mice, soluble protein extracts were detected by 
immunobloting for the indicated proteins (Cyclin D1, CDK1, p16, 
p27, caspase-3 and PARP). β-actin was used to verify equal 
loading. Un-cleaved caspase-3 and PARP and their cleaved 










Figure 23. Effect of doxazosin treatment on the expression level 
of anti-apoptotic/oncogenic/anti-proliferation gene in SKOV-3 
carcinoma cell-derived tumor. 
From xegrafted mice, soluble protein extracts were detected by 
immunoblotting for the indicated proteins (Bcl-2, Bax, survivin, 







Our studies were planned to analyze the mechanism of the 
effects of doxazosin on the JAK/STAT signaling pathway by 
IFN-α or IFN-γ stimulation in ovarian carcinoma cells. This 
was due to the fact that the JAK/STAT pathways are a rising 
interest for targeting cancer-associated diseases, which also 
include cancer treatment. Interferons are multifunctional 
cytokines, as major modulators of the innate and adaptive 
immune system that signal through the JAK/STAT pathway in 
the activation of STAT1/2 (Pestka et al., 2004). In case of a 
response to IFN-α which is preceded by IFN-α binding to 
cell surface receptors, JAK kinases (TYK2 and JAK1) are 
activated, leading to tyrosine phosphorylation of STAT1 and 
STAT2. Generally, cytokines and their cognate transmembrane 
receptors are the essential activators of the JAK/STAT 
pathway. IFNs regulate both anti-viral and immunomodulatory 
activities, while mediating intracellular effects, such as the 
anti-tumor and anti-angiogenic effects. Recently, DAPk1 is a 
major regulator of IFN-γ-induced apoptotic cell death in 
human ovarian carcinoma cells (Yoo et al., 2012). In this study, 
our results strongly indicate a new crucial molecular mechanism 
for doxazosin, which can be reported as a key regulatory factor 
that can target the JAK/STAT signaling cascade. As shown in 
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Figure 9, pre-treatment with IFN-α or IFN-γ significantly 
increased doxazosin-induced apoptotic cell death, which was 
observed through IFN-α or IFN-γ up-regulating doxazosin-
modulated cell growth inhibition. Furthermore, the cleavage of 
PARP, which can be activated by doxazosin alone, was also 
additively promoted via the combinations with IFN-α and 
IFN-γ treatment (Figure 11). 
Activation of STATs can be mediated through IFN-α, IFN-
β, or IFN-γ signaling where it is subsequently translocated 
to the nucleus.  IFN-α/β directly binds to their receptors and 
trigger auto-phosphorylation of the JAK protein families, such 
as JAK1, JAK2, and TYK2. Previous studies have shown that 
STAT1 is involved in mechanisms like cell proliferation and 
apoptotic cell death, so phosphorylation-independent STAT1 
biological functions have been postulated (Mui et al., 1999; 
Chatterjee-Kishore et al., 2000). Meyer et al. (Meyer et al,. 
2002) have reported that STAT1 can be found in both the 
cytoplasm and the nucleus without cytokine induction of cells. 
Also, cytomegaloviral proteins demonstrated a dual biological 
function for STAT2 in anti-viral responses and IFN-γ 
signaling (Zimmermann et al., 2005). In addition, Dengue virus 
NS5 suppresses IFN-α signaling through the blocking of 
STAT2 phosphorylation (Mazzon et al., 2009). Other recent 
studies have revealed STAT2 as a key component of the 
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STAT1-independent mechanism for the protection against 
DENV infection in mice, which has validated that STAT1 and 
STAT2 possess the ability to independently limit the severity 
of DENV pathogenesis (Perry et al., 2011). Interestingly, 
STAT3 up-regulates various proteins involved in cell cycle 
progression, such as Fos, c-Myc, and cyclin D1, and enhances 
anti-apoptotic proteins, such as Bcl-2 and Bcl-xL (Barre et al., 
2003). Thus, STAT3 target proteins are important mediators 
for the regulation of cell cycle progression from the G1 to S 
phase. 
The effects of doxazosin on the biological roles of the IFN-
α or IFN-γ cascade in ovarian tumors have not been fully 
understood. To explain the biological mechanism of cell 
proliferation suppression by doxazosin concerning cell cycle 
changes, we observed both, an inhibition of cell cycle-
regulatory proteins such as cyclin D1 and CDK4, and 
expression of p21 in doxazosin-treated carcinoma cells. As 
indicated in Figure 12 (upper panel), the cell cycle profile of 
the control (un-treatment) cells were not affected significantly, 
except at the S phase section which was gradually down-
regulated by doxazosin, IFN-α or IFN-γ treatment. 
Additionally, the cell cycle profile of the cells treated with 
doxazosin plus IFN-α or doxazosin plus IFN-γ combinations 
were arrested at the G1 phase when compared to the doxazosin  
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single-drug treatment (lower panel). Interestingly, the greatest 
pro-apoptotic effect occurred with the combination of 20 μM 
of doxazosin and 10 ng/ml of IFN-α. These results indicate 
that the activation of apoptosis is contributed by the doxazosin 
plus IFN-α combination-modulated anti-tumor effect. The 
expression of cyclin D1 and CDK4, which are relevant for the 
conversion from the G1 to S phase, was suppressed in a time-
dependent manner. The present study also demonstrated that 
doxazosin significantly down-regulates the phosphorylation of 
JAK/STAT3 in SKOV-3 cells. JAK and STAT inhibitor 
treatment completely restored the doxazosin-reduced 
phosphorylation of each JAK1/2 and STAT1/3. Consistent with 
the results observed in the carcinoma cells, inhibitors for JAK 
and STAT also strongly disturbed doxazosin-reduced JAK or 
STAT activity (Figure 15 and Figure 16). Subsequently, 
doxazosin plus IFN-α or IFN-γ additively suppressed the 
activation of the JAK/STAT pathway, and thus affecting the 
subsequent downstream signaling components, which include 
PI3K, mTOR, 70S6K, and PKCδactivation. 
In conclusion, we have shown that doxazosin can 
significantly inhibit the JAK/STAT signaling pathway through 
caspase-dependent apoptosis, as well as cell cycle arrest by 
IFN-α or IFN-γ stimulation. Growth suppression was 
associated in the ovarian tumor system with the down-
regulation of the JAK/STAT activity that resulted in down-
６１ 
 
stream signaling suppression. These findings provide the first 
exact information on the biological pro-apoptotic mechanisms 
of doxazosin in ovarian carcinoma cells. Therefore, combination 
therapies may be a more useful approach for more advanced 















DOXAZOSIN INHIBITES TUMOR GROWTH AND 
ANGIOGENESIS BY DECRASING VEGFR-2/Akt/mTOR 





Doxazosin is an α1-adrenergic receptor blocker that also 
exerts antitumor effects. However, the underlying mechanisms 
by which it modulates PI3K/Akt intracellular signaling are 
poorly understood. In this study, we reveal that doxazosin 
functions as a novel antiangiogenic agent by inhibiting vascular 
endothelial growth factor (VEGF)-induced cell migration and 
proliferation. It also inhibited VEGF-induced capillary-like 
structure tube formation in vitro. Doxazosin inhibited the 
phosphorylation of VEGF receptor-2 (VEGFR-2) and 
downstream signaling, including phosphatidylinositol-3’-
kinase (PI3K), Akt, 3-phosphoinositide-dependent protein 
kinase 1 (PDK1), mammalian target of rapamycin (mTOR), and 
hypoxia-inducible factor 1α (HIF-1α). However, it had no 
effect on VEGF-induced extracellular signal-regulated kinase 
1/2 (ERK1/2) phosphorylation. Furthermore, doxazosin reduced 
tumor growth and suppressed tumor vascularization in a 
xenograft human ovarian cancer model. These results provide 
evidence that doxazosin functions in the endothelial cell system 
to modulate angiogenesis by inhibiting Akt and mTOR 





Angiogenesis is an important but complex process that occurs 
during endothelial cell development, growth, and movement, as 
well as wound healing and endothelial cell-mediated 
degradation of the extracellular matrix. Multistep angiogenesis 
is vital for cell division and metastasis in most solid tumors. 
Angiogenesis, the constitution of new blood vessels forming 
from pre-existing vessels, occurs during embryonic 
development as well as invasive tumor growth and tumor 
pathogenesis (Folkman et al., 1992; Risau et al., 1997). 
Angiogenesis is activated by various signaling molecules and 
growth factors, including basic fibroblast growth factor (bFGF), 
transforming growth factor beta (TGF-β), and vascular 
endothelial growth factor (VEGF). VEGF is a major modulator 
of endothelial cell function, such as blood vessel formation 
during embryonic development, and plays a vital role in the 
proliferation, migration, and invasion of vascular endothelial 
cells (Ferrara et al., 2002). Angiogenesis is initiated by growth 
factors such as VEGF and is a potential treatment for vascular 
injuries (Yoshiji et al., 1996; Gavin et al., 2004; Kraus et al., 
2004). During cancer, endothelial cell activity plays an essential 
role in modulating various vascular physiological and 
pathological functions. Although VEGF receptor 1 (VEGFR-1) 
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and VEGFR-2 are structurally very similar, they have different 
biological roles. For example, VEGFR-1 negatively regulates 
embryonic vasculogenesis and stimulates tumor angiogenesis 
by activating macrophages, whereas VEGFR-2 is 
predominantly responsible for both tumor angiogenesis and 
embryonic vasculogenesis (Sawano et al., 1996; Ferrara et al., 
2004; Takahashi et al., 2011; Shibuya et al., 2013) VEGFR-2 
also plays a pivotal role in the activation of downstream 
components that are responsible for proliferation, including 
endothelial cell invasion, migration, differentiation, and 
embryonic angiogenesis (Breier et al., 2000; Ferrara et al., 
2000;  Meyer et al., 2003) in contrast, VEGFR-1 has no role in 
endothelial cell proliferation (Meyer et al.,  2004). 
Doxazosin functions as an α1-adrenergic receptor blocker 
(Kirby et al., 1997). It is used to treat patients with benign 
prostatic hyperplasia, a noncancerous enlargement of the 
prostate gland, because α1-blockers relax the smooth muscles 
surrounding the prostate, easing urine flow and decreasing 
bladder outlet obstruction (Benning et al., 2002;  
Tahmatzopoulos et al., 2004). Some previous studies also 
reported that α1-adrenoceptor antagonists stimulate apoptotic 
cell death via transforming growth factor-β1 (TGF-β1) 
signaling and the activation of clear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor-alpha (IκBα) 
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in prostate tumor cells (Benning et al., 2002; Partin et al., 
2003). Doxazosin also stimulates apoptotic cell death in 
response to abnormal cell-matrix interactions (Keledjian et al., 
2003). Garrison and Kyprianou reported that specific caspase-
8 inhibitors could block doxazosin-induced apoptotic cell death 
in benign prostate cells (Garrison et al., 2006). Nevertheless, 
the biological roles of these doxazosin-regulated processes, as 
well as molecular mechanism behind the anti-angiogenic 
effects of doxazosin, remain poorly understood.  
Endothelial cells play a vital role in regulating various 
vascular biological effects and related diseases, including tumor 
growth and maintenance. Most studies on angiogenesis have 
focused on endothelial cell proliferation, migration, and 
capillary-like tubule formation. In the current study, we 
investigated the anti-angiogenic effects of doxazosin in tumors 
using in vitro human umbilical vein endothelial cell (HUVEC) 
and in vivo model systems. We also identified the molecular 
pathways responsible for Akt- and mammalian target of 
rapamycin (mTOR)-dependent endothelial cell growth during 
tumorigenesis. Doxazosin inhibited the phosphorylation of 
signaling modulators downstream of phosphatidylinositol-3’-
kinase (PI3K) including Akt, phosphoinositide-dependent 
protein kinase 1 (PDK1), and mTOR by interacting directly with 
VEGFR-2. Therefore, this interaction results in potent anti-
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angiogenic and antitumor effects. The current findings suggest 




Materials and methods 
 
Cell lines, drug reagents and antibodies  
Human ovarian cancer cell lines (SKOV-3 and OVCAR-3) 
were purchased from the American Type Culture Collection 
(ATCC, Manassas, VA), were grown in DMEM (Life 
Technologies, Gaithersburg, MD) medium supplemented with 
10% fetal bovine serum (FBS) and penicillin/streptomycin (100 
units/ml) at 37℃ in a humidified 5% CO2 incubator. Primary 
HUVECs (Clonetics, San Diego, CA) were grown on 0.3% 
gelatin-coated dishes (Sigma, St. Louis, MO) using EGM-2 
Bullekit medium (Clonetics). Rapamycin was purchased from 
Cell Signaling (Berverly, MA). Doxazosin and other chemicals 
were purchased from Sigma (St. Louis, MO). The following 
primary antibodies were used in this study: anti-phospho-
VEGFR-2 (Y1175), anti-VEGFR-2, anti-phospho-PI3K, 
anti-PI3K, anti-phospho-Akt, anti-Akt, anti-HIF-1α, anti-
phospho-ERK1/2, anti-ERK1/2, anti-PCNA(Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-phospho-PDK1, anti-
PDK1, anti-phospho-4E-BP1, anti-4E-BP1, anti-phospho-
mTOR, anti-mTOR, anti-phospho-p70S6K, anti-p70S6K, 
anti-PCNA, anti-Cyclin D1, anti-survivin, anti-cleaved 
Caspase3(Asp175) (all from Cell Signaling Technology), anti-
CD31, anti-phospho-STAT3(Tyr705) (Abcam, Cambridge, 
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UK), anti-VEGF165 (Ab-1; Oncogene, Cambridge, MA) and 
anti-β-actin (Sigma). 
  
[3H]thymidine incorporation analysis 
[3H]thymidine incorporation was assessed as described 
previously (Meng et al. 2006; Xia et al., 2007). Briefly, 
HUVECs were plated into gelatin-coated plates at a density of 
1.6 × 104 cells/well in DMEM containing 10% FBS and 1% 
penicillin/streptomycin on day 0. After 18 h, the cells were 
rinsed twice with M199 and then incubated in M199 containing 
1% FBS for 6 h. Cells were first incubated with doxazosin, and 
were then induced with VEGF (10 ng/ml, R&D Systems, 
Minneapolis, MN) for 24 h in M199 containing 1% FBS. 
[3H]thymidine (0.5 Ci/ml; Amersham, Arlington, IL) was added 
4 h prior to analysis. High-molecular-mass compounds with 
[3H]-radioactivity were then precipitated using 10% 
trichloroacetic acid for 1 h at 4℃. Cells were solubilized in 0.2 
N NaOH containing 0.1% sodium dodecyl sulfate (SDS), and 
[3H]thymidine incorporation was calculated using a liquid 
scintillation counter (Beckman Coulter, Franklin Lakes, NJ). 
 
Cell migration analysis 
Twenty-four well Transwell chambers (8.0 μm pore size; 
Costar, New York, NY) were used to assay migration and 
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invasion (Meng et al., 2006; Xia et al., 2007). For migration 
analyses, the lower surface of a filter was coated with 10 g/ml 
of gelatin overnight. M199 containing 1% FBS and 10 ng/ml 
VEGF was added to the lower wells. Cells were harvested by 
trypsinization and washed. Next, 1.3 × 105 cells were 
resuspended in 100 μl of fresh DMEM, added to the upper 
chamber, and incubated at 37℃ for 24 h. Cells that had 
migrated to the lower chamber were fixed with methanol, and 
stained with 10 mg/ml H&E. Cells that remained on the surface 
of the upper filter were removed by wiping with a cotton swab. 
Cell migration was then quantified by counting the number of 
stained cells in five random areas of each membrane. 
 
In vitro  tube formation analysis 
Growth factor-reduced Matrigel was added to a 24-well plate 
and polymerized for 30 min at 37℃ (Xia et al., 2007). 
Untreated, mock-treated, or doxazosin-treated HUVECs (3.3 
× 105 cells/well) were then added to the surface of the 
Matrigel. The seeded cells were incubated for 48 h with or 
without 10 ng/ml of VEGF in M199 containing 1% FBS. Images 
were then captured at 40× magnification after washing. The 
length of the formed tubes was measured using an inverted 
microscope equipped with a digital CCD camera and ImageLab 
software (MCM Design, Hillerød, Denmark). The control sample 
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(VEGF-induced control) was defined as 100% tube formation, 
and the percent increase or decrease in tube formation relative 
to the control was measured for each sample. 
 
PI3K activity analysis 
In vitro kinase assays were performed as described previously 
(Arbiser et al., 2007; Duronio et al., 1997; Lee et al., 1999). 
Briefly, cells were seeded at a density of 1.4 × 106 cells/well. 
After an overnight incubation, the cells were treated with 
various concentrations of doxazosin for 6 h and then lysed in 
1% NP-40 lysis buffer containing 20 mM Tris-HCl (pH 7.5), 
100 mM NaCl, 1 mM EDTA, 1 mM MgCl2, 1% NP-40, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), and 0.1 mM sodium 
orthovanadate. After the removal of insoluble materials by 
centrifugation, the supernatants were incubated at 4℃ for 1 h 
with anti-p85 antibodies, followed by protein A-agarose beads 
for an additional 1 h at 4℃. The resulting immunoprecipitates 
were incubated in a kinase reaction buffer mixture containing 
200 µg/ml phosphatidylinositol 3-phosphate and 2 µCi of [-
32P] ATP for 15 min at 37°C. The reaction products were 
developed using autoradiography, and the radioactive lipids 





Western blotting analysis 
Cells were rinsed with phosphate-buffered saline (PBS) and 
lysed in radioimmunoprecipitation assay (RIPA) buffer supplied 
with protease inhibitors. The concentration of protein samples 
was then evaluated using a Bradford protein assay kit (Bio-Rad, 
Hercules, CA). Equal amounts of protein were loaded onto 8-
12% SDS-polyacrylamide gel electrophoresis (PAGE) gels and 
then transferred to polyvinylidene difluoride (PVDF) 
membranes (Bio-Rad). After blocking, the membranes were 
incubated at room temperature with primary antibodies for 1 h. 
They were then rinsed three times in wash buffer, followed by 
incubation with the appropriate horseradish peroxidase (HRP)-
conjugated secondary antibodies. The protein bands were 
developed using an enhanced chemiluminescence (ECL) 
detection system. Protein lysates were prepared by 
homogenizing the frozen tumor tissues. Protein quantitation and 
immunoblotting were then performed as described above with 
30 μg protein/sample. 
 
Xenograft mouse model 
Specific pathogen-free BALB/c-nu/nu mice (5~6 weeks old) 
were purchased from Orientbio (Sungnam, Korea). SKOV-3 
cells (1.0×106) were injected subcutaneously with Matrigel (BD 
Bioscience, MA) into the left flank region of each nude mouse. 
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Tumor sizes were measured by caliper measurements 3 times 
every week. On day 12, per oral treatment of 3 mg/kg of 
doxazosin was done and repeated 5 times per week for 24 days. 
Mice were sacrificed one day after the final treatment and 
tumors were then excised and stored at -80℃ for further study. 
All animal studies were approved by the Institutional Animal 
Care and Use Committee (IACUC) at the Research Institute of 
the National Cancer Center. 
 
Immunohistochemistry 
Tumor samples were collected from mouse xenografts and 
fixed in 10% neutral-buffered formalin (Sigma-Aldrich). Slides 
were then stained using H&E (Sigma-Aldrich) according to the 
manufacturer’s instructions. For immunohistochemistry, 
paraffin-embedded ovarian tumor tissues were serially 
sectioned into 5 μm slices. The prepared slides were then 
deparaffinized, rehydrated in xylene and graded alcohols, and 
then rinsed in PBS. The slides were also incubated in 5% 
hydrogen peroxide in methanol for 20 min to block endogenous 
peroxidase activity. Sections were incubated with a saturating 
concentration of anti-mouse CD31 (platelet-derived 
endothelial cell adhesion molecule; PECAM-1) (Abcam) 
antibody overnight at 4℃, followed by a alkaline phosphatase 
(AP)-conjugated secondary antibody at room temperature for 
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1 h. Microvessel density (MVD) was quantified in five randomly 
selected individual tumor fields (at 40× magnification) per 
sample, and the number of microvessels was counted under a 
high-powered microscope (400× magnification).  
 
Statistical analysis 
Results were analyzed statistically using Student’s t-test for 
comparisons between two groups. Data are presented as the 
means ± SDs, or SEM for triplicate experiments. Statistical 
significance was defined as P<0.05. Values with 95% 
confidence (P<0.05) are depicted with an asterisk (*) on each 
graph. Statistical significance was defined as P<0.01. Values 
with 99% confidence (P<0.01) are depicted with an asterisk 





Doxazosin significantly suppressed VEGF-induced cell 
proliferation, migration, and capillary-like tubule formation in 
HUVECs 
Physiological activity of endothelial cell plays a vital role in 
regulating various vascular biological functions and diseases, 
including tumor growth and maintenance. The detailed 
molecular mechanism on doxazosin effects in endothelial cells 
during tumor growth has not been yet. Generally, angiogenesis 
was investigated based on cell proliferation, migration, and 
capillary-like tubule formation in endothelial cells.  
The migration of endothelial cells is essential during 
angiogenesis. Therefore, we explored whether doxazosin 
modulated the effects of VEGF on cell migration using a 
modified Boyden Transwell chamber system in HUVECs. As 
expected, VEGF promoted the migration of doxazosin-treated 
cells compared to control cells. Doxazosin inhibited migration in 
a dose-dependent manner, and the maximal effect was seen at 
a concentration of 20 μM (Figure 24). No migration was 
observed after 24 h of treatment with increasing concentrations 
(0-25 μM) of doxazosin (data not shown). These results 
suggest that VEGF-stimulated endothelial cell migration and 
angiogenesis might be inhibited specifically by doxazosin. 
７６ 
 
The in vitro anti-angiogenic activity of doxazosin was 
analyzed by assessing its effects on the VEGF-stimulated 
proliferation of endothelial cells using [3H]thymidine 
incorporation. Doxazosin inhibited VEGF-induced HUVEC DNA 
synthesis significantly (Figure 25). This anti-proliferative 
effect was not due to the cytotoxicity of doxazosin in 
endothelial cells, since doxazosin had no effect on the viability 
of HUVECs, as assessed using Trypan Blue exclusion (data not 
shown). These results suggest that doxazosin regulates 
angiostasis and potently inhibits VEGF-induced pivotal events 
during angiogenesis, including endothelial cell proliferation and 
migration in vitro.  
We next assessed the anti-angiogenic effects of doxazosin 
on VEGF-induced capillary-like tubule formation using 
HUVECs grown on Matrigel in vitro. As shown in Figure 26, 
treatment with VEGF increased the formation of extended, 
strong capillary-like tubular structures compared with control 
cells. In contrast, doxazosin treatment abrogated VEGF-
induced capillary-like tubule formation. Collectively, these 
results strongly suggest that doxazosin specifically regulates 







Figure 24. Doxazosin inhibited migration in a dose-dependent 
manner.  
To address whether doxazosin-treatedcontrols the effects of 
VEGF on endothelial cell migration, they were assessed using 
the Boyden chamber for the migration assay system. Cells were 
plated in the top chamber of the Boyden Transwell chamber 
(pore size; 8 μm). All cells were treated with increasing 
concentrations of doxazosin, fixed, and then stained with H & E. 
The numbers of the migrated cells were calculated under a light 
microscope. Three independent experiments were assayed in 
triplicate. Data are presented as the mean±SD. *P<0.05 versus 










Figure 25. Treatment of doxazosin decreases angiogenic activity 
in endothelial cell proliferation. 
The c.p.m. value of [3H]thymidine was evaluated using a liquid 
scintillation counter. The data are the mean±SD of three 
independent experiments. Data are presented as the mean±SD. 







Figure 26. Treatment of doxazosin decreases angiogenic activity 
in endothelial cell tube formation.  
After treatment with doxazosin, they were grown on growth 
factor-reduced Matrigel. Cells were incubated with or without 
10 ng/ml of VEGF. The formation of tubular-like structures 
was monitored by the inverted microscope. Tube lengths were 
quantified and expressed as mean±SD. Experiments were 
repeated three times and a representative result was shown. 
*P<0.05 compared to control. 
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Doxazosin suppresses PI3K and Akt phosphorylation in a 
concentration-dependent manner 
The phosphorylation of PI3K/Akt is an essential process for 
signaling pathways in tumor angiogenesis.  Akt plays a vital 
role as a down-stream messenger of PI3K and is also 
controlled by several growth factors, such as insulin-like 
growth factor-1 (IGF-1), and transforming growth factor-β1 
(TGF-β1), and epidermal growth factor (EGF). Therefore, we 
evaluated whether doxazosin decreased PI3K and Akt 
phosphorylation in SKOV-3 and OVCAR-3 (data not shown) 
ovarian carcinoma cells. Lysates from SKOV-3 cells treated 
with various concentrations (0~25 μM) of doxazosin were 
analyzed by Western blot analysis, which observed that the 
VEGF-induced phosphorylation of PI3K and Akt that played an 
important role in VEGF-stimulated angiogenesis. As shown in 
Figure 27 and Figure 28, the activity of PI3K-treated with 
various concentrations of doxazosin was inhibited a dose-
dependent manner, the maximum effect was observed with 20 
µM. Consistent with this result, 20 μM doxazosin also 
decreased PI3K phosphorylation significantly. Akt is an 
essential downstream component of PI3K signaling. As 
expected, doxazosin gradually reduced Akt phosphorylation in 
a dose-dependent manner (Figure 29). Similarly, doxazosin 
also lowered Akt phosphorylation in HUVECs (data not shown). 
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Collectively, these results suggest that PI3K/Akt-dependent 
signaling cascades play important roles in the effects of 
doxazosin in endothelial cells. The magnitude of the observed 
effects was comparable to those exerted by well-known PI3K 
and mTOR inhibitors such as wortmannin and rapamycin, 
respectively. 
 As expected, doxazosin conspicuously decreased the 
phosphorylation of Akt (Ser473) (Figure 30) and the phospho
rylation of eukaryotic translation initiation factor 4E-BP1 
(Tyr37/46) (Figure 31), as well as the phosphorylation of 
PDK1 (Ser241) (Figure 32), one of the best- characterized 
targets of the mTOR. Subsequently, when doxazosin was co-
treated with rapamycin, an inhibitor of mTOR, p-4E-BP1 was 
inactivated. These results provide evidence to support our 
hypothesis that doxazosin inhibits PI3K/Akt activity.  
We next assessed the effects of doxazosin on downstream 
mediators of the PI3K/Akt pathways. Doxazosin dramatically 
diminished the phosphorylation of mTOR at Ser-2448 and 
p70S6K at Thr-421 (Figure 32). Therefore, we next 
determined whether doxazosin led to VEGF-induced activation 
of the Akt/PDK1/mTOR complex. As shown in Figure 33, 
doxazosin decreased the VEGF-induced phosphorylation of 
Akt (Ser-473 and Thr-308), PDK1 (Ser-241), and mTOR 
(Ser-2448), but had no effect on the phosphorylation of 
８２ 
 
ERK1/2. These results strongly suggest that doxazosin 
decreases VEGF-dependent Akt, PDK1, and mTOR phospho
rylation.  
PI3K/Akt signaling not only mediates VEGF-induced 
cell proliferation and migration, but also the expression of 
VEGF and HIF-1α (Tahmatzopoulos et al., 2004). Consistent 
with these findings, doxazosin treatment abrogated VEGF and 
HIF-1α expression completely. These results suggest that 
VEGF-induced protein activation is inhibited specifically by 
doxazosin in HUVECs (Figure 34) and ovarian carcinoma cells 
(Figure 35). Collectively, these observations suggest that 
doxazosin inhibits the autocrine effects of VEGF in endothelial 
cells, exerts direct antiangiogenic effects, and inhibits tumor 









Figure 27. Doxazosin down-regulates PI3K activity (From Park 
et al., 2014). 
The inhibitory effect on PI3K activity in the presence of 
doxazosin was measured using the in vitro PI3 kinase assay 











Figure 28. Doxazosin down-regulates PI3K phosphorylation. 
Cells were treated with increasing concentrations of doxazosin, 
harvested, and detected to immunoblotting for the indicated 
dose proteins. PI3K was used to verify the equal loading of the 














Figure 29. Doxazosin down-regulates Akt phosphorylation on 
dose dependent manner. 
Cells were treated with various concentrations of doxazosin. 
Phosphorylation of Akt was evaluated using Western blot 











Figure 30. Doxazosin down-regulates Akt phosphorylation. 
Cells were treated with doxazosin, rapamycin as an mTOR 
inhibitor, rapamycin plus doxazosin, and wortmannin as a PI3K 
inhibitor, respectively. Immunoblotting for un-phosphorylated 
Akt was used as a loading control. *P<0.05 compared to control; 














Figure 31.  Doxazosin down-regulates 4E-BP1 phosphorylation.  
Cells were treated with doxazosin, rapamycin as an mTOR 
inhibitor, rapamycin plus doxazosin, and wortmannin as a PI3K 
inhibitor, respectively. Immunoblotting for un-phosphorylated 








Figure 32. Doxazosin down-regulates mTOR target pathway 
phosphorylation and HIF-1α and VEGF165 expression. 
After doxazosin treatment, cells were collected for Western 
blot analysis for the phosphorylated and non-phosphorylated 
proteins (PDK1, mTOR, 70S6K). β-actin served as a loading 







Figure 33. Doxazosin suppressed VEGF-dependent Akt, PDK1, 
and mTOR phosphorylation.  
After treatment with doxazosin, cells were harvested for 
immunoblotting analysis with antibodies specific for 
phosphorylated or non-phosphorylated proteins indicated for 
Akt phosphorylation, and the phosphorylation of down-stream 
components, including PDK1, mTOR, and ERK1/2. *P<0.05 









Figure 34. Doxazosin inhibits VEGF-induced HIF-1α and 
VEGF  in HUVECs.  
Cells were incubated with 10 ng/ml VEGF and then control-
treated or treated with doxazosin in HUVECs. HIF-1α  and 
VEGF protein expression was then developed by Western blot 
analysis. Three independent experiments were conducted in 








Figure 35. Doxazosin inhibits VEGF-induced HIF-1α and VEGF 
in ovarian carcinoma cells.  
SKOV-3 cells were incubated with 10 ng/ml VEGF and then 
control-treated or treated with doxazosin in ovarian carcinoma 
cells. HIF-1α and VEGF protein expression was then 
developed by Western blot analysis. Three independent 




Doxazosin inhibits VEGF-induced VEGFR-2 phosphorylation 
and VEGFR-2-dependent transcription 
VEGFR-2 is a key signal transducer during VEGF-induced 
endothelial cell vascular development and pathological 
angiogenesis. We next assessed the effect of doxazosin on 
VEGF-induced VEGFR-2 phosphorylation in SKOV-3 cells 
and HUVECs (data not shown) to assess the biological and 
functional relevance of the direct relationship between 
VEGFR-2 and doxazosin. As shown in Figure 36, treatment 
with doxazosin suppressed VEGF-induced VEGFR-2 
phosphorylation in SKOV-3 carcinoma cells. The effect of 
doxazosin on VEGFR-2 transcription was then evaluated using 
a luciferase reporter assay system and a construct containing 
the VEGFR-2 promoter fused to luciferase. Luciferase activity 
decreased in response to treatment with doxazosin in a dose-
dependent manner (Figure 37), suggesting that doxazosin 
regulates VEGFR-2 activity. These results suggest that 










Figure 36. Doxazosin inhibits VEGF-induced VEGFR-2 
phosphorylation and VEGFR-2-dependent transcription.  
Cells were incubated with 10 ng/ml VEGF and then control-
treated or treated with doxazosin. Total cell lysates were 
prepared and detected for VEGFR-2 phosphorylation levels 
through immnunoblot analysis. Unphosphorylated VEGFR-2 
and β-actin were used as the loading control. *P<0.05 









Figure 37. Suppression of VEGFR-2-dependent transcription 
by doxazosin.  
Cells were co-transfected with 500 ng of VEGFR-2-Luc, 500 
ng of a VEGFR-2 expression plasmid (pcDNA3.1/VEGFR-2), 
and increasing concentrations of doxazosin 0, 5, 15, and 25 
μM). Assays were performed as described previously and the 
VEGFR-2-Luc and VEGFR-2 expression plasmid were 
provided by Dr. S.B. Rho (Rho et al., 2012). The values are 
presented as the mean±SD. *P<0.05 compared to control.  
９６ 
 
Doxazosin inhibits tumor growth by antiangiogenic activity in 
vivo 
We next determined whether doxazosin has direct effects on 
angiogenesis and tumor cell growth in vivo. SKOV-3 ovarian 
cancer cells were injected subcutaneously into nude mice 
(10/group), and the tumors were allowed to grow for 12 days 
until they reached a mean volume of 100 mm3. The mice were 
treated orally with control or doxazosin, and tumor growth and 
morphology was evaluated every 3 days for 24 days. 
Doxazosin-treated tumors weighed ~75% less than those from 
control mice (Figure 38, upper panel). Hematoxylin and eosin 
(H&E) staining revealed that tumors in the control group were 
high-grade carcinoma with an irregular cell distribution. In 
contrast, doxazosin-treated tumors exhibited large areas of 
late-apoptotic or necrotic cells (Figure 38, lower panel). 
Tumors treated with doxazosin had significantly reduced cell 
proliferation protein (including cyclin D1, survivin) and 
enhanced apoptotic cell death proteins, as determined by 
westernblotting for PCNA and PARP. In addition, VEGF 
expression and the phosphorylation of VEGFR-2 were 
decreased in doxazosin treated tumors (Figure 39). Moreover, 
anti-CD31 (PECAM-1) staining in the endothelial cells of 
doxazosin-treated mice revealed a ~2.5-fold reduced number 
of blood vessels compared to the control (Figure 40). These 
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results suggested that doxazosin treatment is capable of 










Figure 38.  Doxazosin suppressed tumor growth . 
SKOV-3 ovarian carcinoma cells injected subcutaneously in 
nude mice.  Mean tumor weight was monitored at the end of the 




Figure 39.  Doxazosin suppressed tumor growth related protein. 
Tumor tissues were evaluated using immunoblot analysis with 
indicated cell proliferate protein PCNA, cyclin D1, VEGF, 
survivin, p-VEGFR-2 and cell death protein PARP antibodies. 










Figure 40. Doxazosin suppressed tumor growth by inhibiting 
angiogenesis in vivo . 
CD31 staining was performed to visualize the blood vessels 
(arrows) in tumor tissues. Frozen sections of the tumors were 
stained for endothelial cells using an anti-CD31 (PECAM-1) 







In this study, we identified a novel biological function of 
doxazosin as a powerful anti-angiogenic modulator that 
functions via the Akt/mTOR signaling pathway. Quinazoline-
derived α1-adrenoceptor antagonists exert anticancer activity 
in prostate cancer. In addition, the induction of apoptotic cell 
death and inhibition of angiogenesis by doxazosin have been 
reported widely (Ferrara et al., 2000; Meyer et al., 2003; 
Meyer et al., 2004; Kirby et al., 1997; Benning et al., 2002). 
Nevertheless, its precise molecular effects have not yet been 
reported in ovarian cancer. The phosphorylation of VEGFR-2 
plays an important role in promoting VEGF-induced tumor 
angiogenesis. During cancer progression, angiogenesis is 
typically regulated by two key factors: VEGF, and HIF 
transcription factors. HIF proteins commonly enhance the 
expression of VEGF, whereas HIF-1α expression is enhanced 
during hypoxia (Ferrara et al., 2000). Activated HIF-1α 
promotes the proliferation, migration, and invasion of 
endothelial cells, as well as tube formation in cancer. The 
upregulation of VEGF is commonly seen in most aggressive 
solid tumors, including ovarian, colon, lung, and uterine tumors; 
it is closely associated with tumor progression and a poor 
prognosis (Partin et al., 2003; Keledjian et al., 2003; Garrison 
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et al., 2006; Jiang et al., 2008). However, the current study 
revealed that doxazosin could decrease both HIF-1α and 
VEGF expression during angiogenesis (Figures 32, 34 and 35). 
Treatment with doxazosin also suppressed VEGF-induced 
HUVEC proliferation significantly compared to the VEGF-
treated control (Figure 21). Subsequently, we confirmed that 
doxazosin dramatically reduced the phosphorylation of PI3K 
and mTOR, as well as VEGFR-2 protein expression (Figures. 
28, 32, and 36). These results clearly suggest that doxazosin 
inhibits endothelial cell angiogenesis during tumorigenesis. 
PI3K/Akt signaling plays a vital role in the biological 
functions of human malignant tumors. Recent studies have 
reported that suppressing PI3K might be beneficial to inhibit 
tumor angiogenesis (Tahmatzopoulos et al., 2004; Olson et al., 
1994; Paley et al., 1997; Ishigami et al., 1998). PI3K also 
regulates the signaling pathways that are involved in cell 
growth and/or apoptotic cell death (Jiang et al., 2008). 
Therefore, the anti-apoptotic events that are modulated by Akt 
begin with PI3K. Akt is activated by PI3K, which recruits Akt to 
the cell membrane and allows its phosphorylation by PDK1 
(Ohta et al., 1999). The current study revealed that doxazosin 
decreased the phosphorylation of both PDK1 and Akt (Figures 
29 and 32). In addition, doxazosin decreased the VEGF-
induced phosphorylation of the mTOR signaling mediator 
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p70S6K and 4E-BP1. In contrast, VEGF-induced ERK1/2 
phosphorylation was unaffected by doxazosin (Figure 33). 
Collectively, these results suggest that doxazosin could block 
VEGFR-2 transcriptional activity by suppressing VEGFR-2 
phosphorylation via VEGF-dependent Akt/mTOR signaling. 
In summary, our data demonstrate that doxazosin could 
suppress endothelial cell functions, including cell proliferation, 
migration, invasion, and capillary-like tubule formation, by 
suppressing VEGFR-2 phosphorylation and inhibiting 
Akt/mTOR signaling. It also suppresses the expression of HIF-
1α and VEGF in ovarian carcinoma cells. These data supply 
additional evidence to support a role for doxazosin as a potent 
modulator of the biological and physiological mechanisms 
relevant to angiogenesis. The potential of doxazosin as an 




GENAERAL DISCUSSION AND CONCLUSION  
 
Our studies were planned to analyze the mechanism of the 
effects of doxazosin on JAK/STAT signaling induced by IFN-α 
or IFN-γ stimulation in ovarian carcinoma cells. Interferons 
are multifunctional cytokines. They are major modulators of the 
innate and adaptive immune systems that signal through the 
JAK/STAT pathway by activation of STAT1/2 (Pestka et al., 
2004). In this study, our results strongly indicate a new crucial 
molecular mechanism of doxazosin, which is a key regulatory 
factor that can target the JAK/STAT signaling cascade. Pre-
treatment with IFN-α or IFN-γ significantly increased 
doxazosin-induced apoptotic cell death and up-regulated 
doxazosin-modulated cell growth inhibition. The cleavage of 
PARP which can be activated by doxazosin alone was also 
increased by IFN-α and IFN-γ. To explain the biological 
mechanism of cell proliferation suppression by doxazosin in 
terms of cell cycle changes, we observed both inhibition of cell 
cycle-regulatory proteins such as cyclin D1 and CDK4 and 
expression of p21 in doxazosin-treated carcinoma cells. As 
indicated in Chapter 1, cells treated with doxazosin plus IFN-α 
or doxazosin plus IFN-γ were arrested in the G1 phase. The 
greatest pro-apoptotic effect occurred with the combination of 
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doxazosin and IFN-α. These results indicate that the 
activation of apoptosis contributed to the anti-tumor effect of 
doxazosin plus IFN-α. The expression of cyclin D1 and CDK4, 
which are relevant for the transition from the G1 to the S phase, 
was suppressed in a time-dependent manner. The present 
study also demonstrated that doxazosin significantly down-
regulates the phosphorylation of JAK/STAT in SKOV-3 cells. 
JAK and STAT inhibitor treatment completely restored the 
doxazosin-reduced phosphorylation of JAK1/2 and STAT1/3. 
Consistent with the results from carcinoma cells, inhibitors of 
JAK and STAT also strongly inhibited doxazosin-reduced JAK 
and STAT activity. Also, doxazosin and IFN-α or IFN-γ 
additively suppressed activation of the JAK/STAT pathway, 
thereby affecting downstream signaling components, which 
include PI3K, mTOR, 70S6K, and PKCδ activation. We further 
identified a novel biological function of doxazosin as a powerful 
anti-angiogenic modulator that functions via the Akt/mTOR 
signaling pathway. The phosphorylation of VEGFR-2 plays an 
important role in promoting VEGF-induced tumor angiogenesis. 
Activated HIF-1α promotes the proliferation, migration, and 
invasion of endothelial cells, as well as tube formation in cancer. 
VEGF is frequently upregulated in most aggressive solid tumors, 
including ovarian, colon, lung, and uterine tumors, and is closely 
associated with tumor progression and poor prognosis (Ferrara 
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et al., 2000; Partin et al., 2003, Keledjian et al., 2003; Garrison 
et al., 2006; Jiang et al., 2008). However, the current study 
revealed that doxazosin decreased both HIF-1α and VEGF 
expression during angiogenesis. Treatment with doxazosin also 
significantly suppressed VEGF-induced HUVEC proliferation 
compared to the VEGF-treated control. Subsequently, we 
confirmed that doxazosin dramatically reduced the phosp
horylation of PI3K and mTOR, as well as VEGFR-2 protein 
expression. These results clearly suggest that doxazosin 
inhibits angiogenesis during tumorigenesis. Recent studies 
suggest that suppressing PI3K might inhibit tumor angiogenesis 
(Tahmatzopoulos et al., 2004; Olson et al., 1994; Paley et al., 
1997; Ishigami et al., 1998). Akt is activated by PI3K, which 
recruits Akt to the cell membrane and allows it s phosp
horylation by PDK1 (Ohta et al., 1999). In the current study, 
doxazosin decreased the phosphorylation of both PDK1 and Akt. 
It also decreased the VEGF-induced phosphorylation of the 
mTOR signaling mediator p70S6K and 4E-BP1. By contrast, 
VEGF-induced ERK1/2 phosphorylation was not affected by 
doxazosin. Collectively, these results suggest that doxazosin 
blocked VEGFR-2 transcriptional activity by suppressing 
VEGFR-2 phosphorylation via VEGF-dependent Akt/mTOR 
signaling. These findings provide the first detailed information 
on the biological pro-apoptotic mechanisms of doxazosin in 
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ovarian carcinoma cells. Our data demonstrate that doxazosin 
suppressed endothelial cell functions, including cell proliferation, 
migration, invasion, and capillary-like tubule formation, by 
suppressing VEGFR-2 phosphorylation and inhibiting Akt/mTOR 
signaling. These data provide additional evidence to support a 
role for doxazosin as a potent modulator of biological and 
physiological mechanisms relevant to angiogenesis. Doxazosin 
combination therapies may be a useful approach for more 





JAK/STAT 인산화 및  
VEGFR-2/Akt/mTOR 신호전달  




서울대학교 대학원 수의학과 수의병리학 전공 
 
독사조신은 남성의 전립선비대증과 고혈압에 사용되는 약물로 
alpha1-adrenergic receptor 에 작용하는 것으로 알려져 있으며 전립선
세포 과증식에 대한 처리시 이를 억제하는 효과를 보이는 것으로 
확인된 바 있었다. 그러나 그 정확한 기전은 아직 잘 알려져 있지 
않음으로, 본 연구에서는 여성의 난소암 세포주와 동물모델을 
사용하여 해당 물질의 난소암 성장억제 효과를 확인하고 자 한다.  
독사조신은 처리농도 및 처리시간에 따라 점차적으로 난소암 세포주의 
성장억제를 유발하였으며, 이러한 효과는 독사조신, IFN-α 또는 
IFN-γ 단독과 비교해 볼 때 독사조신과 IFN 을 함께 사용하는 
경우에서 더욱 활성화되었다. 세포사멸과 관련있는 caspase-3 및 
PARP 의 활성화 증가와 함께 세포분열과 관련있는 cyclin D1 과 CDK
4 의 감소를 확인하였다. 이러한 독사조신의 효과는 JAK 와 STAT 특
이적인 억제제에 의해 방해되었다. 본 연구에서는 IFN 과 독사조신의 
처리를 통해 JAK 과 STAT 의 인산화를 조절할 수 있었으며, 그 결과 
JAK/STAT 신호전달체계 하위과정인 PI3K, mTOR, p70S6K 과 P
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KCδ를 조절한다는 것을 알 수 있었다. 난소암 이종이식 동물모델을 
사용한 실험에서는 독사조신 처리에 의해 종양 성장이 억제되는 것을 
확인할 수 있었다. 독사조신에 의한 난소암 혈관신생억제에대한 
효과를 확인하기 위해서 HUVECs, 난소암 세포주와 난소암 세포주 
이종이식 동물모델을 이용한 연구를 수행한 연구에서 독사조신 처리는 
VEGF 에의한 HUVECs 의 migration, proliferation 와 tube 
formation 을 억제하였다. 독사조신은 VEGF 및 HIF-1α의 발현을 
억제하고, VEGFR-2 전사와 VEGFR-2 인산화를 억제하였다. 
VEGF 처리후, PI3K, Akt, PDK1, mTOR 의 인산화를 억제하였으나, 
ERK1/2 인산화는 억제하지 않았다. 그러므로 독사조신은 VEGFR-
2/Akt/mTOR 의 신호 전달 체계를 통해 혈관신생을 억제하는 것으로 
확인되었다. 난소암 이종이식 동물모델을 사용한 실험에서는 독사조신 
처리에 의해 혈관생성이 억제되어 있었으며, VEGFR-2 의 인산화가 
감소되어 있었다. 본 논문은 독사조신의 JAK/STAT 기전 인산화 
억제를 통한 난소암세포 성장억제효과와 VEGFR-2 신호전달체계를 
통한 혈관신생 억제효과를 지니고 있음을 처음으로 밝혔다. 위와 같은 
결과를 활용한다면 난소암 항암치료에 대한 새로운 전략을 제안할 수 
있다고 본다.  
  
Keywords:  독사조신, 난소암, IFN, JAK, STAT, Akt, mTOR, 
VEGFR-2 
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